(MedPage Today) — CHICAGO — In patients with type 2 diabetes and obesity, use of GLP-1 receptor agonists was associated with a lower risk of obesity-related cancers and death from any cause, a target trial emulation study found.
In a matched…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115732
Author :
Publish date : 2025-05-22 21:40:00
Copyright for syndicated content belongs to the linked Source.
